Alumis Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALMS research report →
Range $15 – $40
Price Chart
About the company
Alumis Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
- CEO
- Martin Babler
- IPO
- 2024
- Employees
- 238
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on ALMS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $514.09M
- P/E
- -1.27
- Fwd P/E
- 2.13
- PEG
- 0.01
- P/S
- 78.58
- P/B
- 1.50
- EV/EBITDA
- -1.28
- Div Yield
- 0.00%
- Gross Margin
- 87.97%
- Op Margin
- -6116.66%
- Net Margin
- -5844.54%
- ROE
- -99.61%
- ROIC
- -106.42%
Latest fiscal year · YoY change
- Revenue
- $24.05M+0.0%
- Gross Profit
- $20.55M+752.1%
- Op Income
- $-427,204,000
- Net Income
- $-243,325,000+17.3%
- EPS
- $-2.32+77.6%
- OCF Growth
- -44.9%
- FCF Growth
- -44.1%
- 52W High
- $31.35
- 52W Low
- $3.94
- 50D MA
- $6.79
- 200D MA
- $20.01
- Beta
- -0.67
- RSI (14)
- 26
- Avg Volume
- 2.86M
No earnings-call transcripts are available for ALMS yet.
- Free Float
- 70.9%
- Shares Outstanding
- 129.44M
- Float Shares
- 91.73M
of shares held by institutions
213 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ayurmaya Capital Management Company, LP | 15.14M | 0 |
| Blackrock, Inc. | 8.58M | ▲ 360.25K |
| Deep Track Capital, LP | 6.35M | ▼ 424.04K |
| Samsara Biocapital, LLC | 6.35M | 0 |
| Foresite Capital Management V, LLC | 5.90M | 0 |
| Price T Rowe Associates Inc | 5.20M | ▲ 1.91M |
| Venbio Partners LLC | 4.53M | 0 |
| Vanguard Capital Management LLC | 4.26M | ▲ 41.76K |
| Foresite Capital Management Vi LLC | 4.25M | 0 |
| Vanguard Group Inc | 4.10M | ▲ 73.67K |
| Nextech Invest Ltd. | 3.54M | 0 |
| Cormorant Asset Management, LP | 3.29M | ▼ 663.64K |
Held by 261 ETFs
Biggest fund positions in ALMS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 2, 26 | Schroer John R. | sell | 794 |
| Nov 2, 26 | Pangali Sanam | sell | 332 |
| Nov 2, 26 | Hardiman Roy C. | sell | 652 |
| Nov 2, 26 | Goldstein David M | sell | 629 |
| Nov 2, 26 | Drappa Jorn | sell | 593 |
| Nov 2, 26 | Bradley Mark Christopher | sell | 623 |
| Sep 8, 26 | AKKARAJU SRINIVAS | buy | 273,291 |
| Sep 4, 26 | AKKARAJU SRINIVAS | buy | 220,070 |
| Sep 8, 26 | AKKARAJU SRINIVAS | sell | 48,066 |
| Sep 8, 26 | AKKARAJU SRINIVAS | buy | 273,290 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ALMS coverage
Recent articles, reports, and earnings notes.
No research on ALMS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALMS report →Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
globenewswire.com · Nov 12
Alumis Inc. (NASDAQ:ALMS) Stock Has Consensus Target Price of $33.27 According to Brokerages
defenseworld.net · Nov 6
Alumis Inc. (NASDAQ:ALMS) Stock Has Consensus Target Price of $33.27
defenseworld.net · Oct 12
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
globenewswire.com · Oct 9
Tango Therapeutics (NASDAQ:TNGX) vs. Alumis (NASDAQ:ALMS) Financial Analysis
defenseworld.net · Oct 6
Alumis (NASDAQ:ALMS) & Pyxis Oncology (NASDAQ:PYXS) Head-To-Head Review
defenseworld.net · Sep 16
Financial Survey: Alvotech (NASDAQ:ALVO) & Alumis (NASDAQ:ALMS)
defenseworld.net · Sep 15
Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.